Drug intelligence / Profile preview

capecitabine + celecoxib

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Capecitabine + celecoxib is a combination therapy that pairs capecitabine, a nucleoside metabolic inhibitor, with celecoxib, a COX-2 inhibitor. This combination has demonstrated synergistic antitumoral effects in various cancer models, particularly in colorectal cancer. Additionally, celecoxib has been shown to prevent or reduce the severity of hand-foot syndrome, a common adverse effect of capecitabine. Pharmacokinetic studies have revealed that coadministration of capecitabine increases exposure to celecoxib, with the interaction persisting for at least 7 days after capecitabine discontinuation.

Targets

TS (Thymidylate synthase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on capecitabine + celecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + celecoxib.

Explore the full profile